Adapted from Elovic EP, et al. 20088
Patients reinjected every 12 weeks starting at week 0.
Botulinum toxin type A <250 U: n=66.
All changes from baseline were significant (p<0.01).
Study context: A multi-centre, open-label, repeated-dose study, to assess the safety and evaluate the effects of repeated treatments with BOTOX® on functional disability, quality of life and muscle tone of patients with upper limb post-stroke spasticity, as well as its effect on caregivers.8